Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Industry: Medical Technology (Spinal Implants and Biologics)
Alphatec is a medical technology company focused on the design, development, manufacturing, and marketing of products for the surgical treatment of spine disorders. The company operates primarily in the U.S. and Asia (Japan), with plans to expand into Europe in 2008. Its strategy emphasizes a "surgeons' culture," in-house manufacturing capabilities, and a broad product portfolio addressing degenerative conditions, deformities, and the aging spine market.
Key Financial Metrics (Year Ended Dec 31, 2007)
| Metric | 2007 (in thousands) | 2006 (in thousands) |
|---|---|---|
| Revenues | $80,031 | $74,005 |
| Cost of Revenues | $29,824 | $25,700 |
| Gross Profit | $50,207 | $48,305 |
| Gross Margin | 62.7% | 65.3% |
| Total Operating Expenses | $69,893 | $70,419 |
| Operating Loss | $(19,686) | $(22,114) |
| Net Loss | $(20,202) | $(25,816) |
| Cash and Cash Equivalents | $25,843 | $16,943 |
| Working Capital | $39,802 | $24,108 |
| Total Debt (Current + Long-term) | $4,165 | $5,171 |
Note: The company recorded a significant non-cash expense of $9.3 million in 2007 for In-Process Research and Development (IPR&D) related to new license acquisitions.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8.1% to $80.0 million, driven primarily by a $6.1 million increase in U.S. sales of Zodiac, Novel, Trestle, and Solanas product lines. Asia revenues remained relatively flat due to a planned reduction in non-spine revenue offset by the acquisition of Japan Ortho Medical.
- Gross Margin Compression: Gross margin decreased 2.6 percentage points to 62.7%. This was primarily due to unfavorable production variances, inventory write-offs, increased instrument depreciation, and higher royalty expenses, partially offset by lower excess and obsolete inventory provisions.
- Operating Expenses: Total operating expenses decreased slightly ($0.5 million) despite a $9.3 million increase in IPR&D charges. This was due to significant reductions in General and Administrative expenses ($9.5 million decrease) driven by lower severance costs and the absence of a 2006 IPO-related bonus, as well as a decrease in Sales and Marketing expenses ($3.2 million).
- Liquidity: Cash and cash equivalents increased by $8.9 million to $25.8 million, bolstered by $32.2 million in net proceeds from a secondary public offering in September 2007.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy
Management expects to begin selling products in Europe in 2008. The company plans to consolidate its operations into two new adjacent facilities in Carlsbad, California, in the third quarter of 2008 to improve efficiency. The company believes its current cash, operating revenues, and credit facilities are sufficient to fund operations through January 1, 2009.
Key Risks
- Patent Litigation: The company is a defendant in a patent infringement suit filed by Biedermann Motech GmbH and DePuy Spine, Inc. regarding the 678 Patent, which covers certain pedicle screw designs. An adverse outcome could materially harm the business as Zodiac and Solanas products represent a significant portion of revenue.
- Supplier Concentration: The company relies on a single supplier, Invibio, for PEEK (polyetheretherketone), a critical raw material used in 19.7% of 2007 revenues. Supply interruptions could disrupt manufacturing.
- Reimbursement: Sales depend on third-party payor reimbursement. Changes in Medicare or private insurance policies could reduce demand or pricing power.
- Profitability: The company has a history of operating losses and will need to generate significant net revenues to achieve profitability.
Unusual Items
The 2007 financial results include a $9.3 million charge for IPR&D related to the acquisition of exclusive licenses for the GLIF system, V-Stent, and OsseoScrew technologies. Additionally, the company recorded a $2.0 million reversal of severance expenses in 2007 following a settlement with prior executives.
Investor Verification Checklist
- Patent Litigation Status: Verify the current status of the Biedermann/DePuy lawsuit regarding the 678 Patent and the potential impact on the Zodiac and Solanas product lines.
- European Expansion: Confirm the timeline and regulatory clearance status for product sales in Europe, which was planned for 2008.
- Supply Chain Resilience: Assess the risks associated with the single-source supply agreement for PEEK material with Invibio.
- IPR&D Commercialization: Monitor the development progress and regulatory approval timelines for the newly licensed technologies (GLIF, V-Stent, OsseoScrew) to determine when they might contribute to revenue.
- Cost Control: Evaluate the sustainability of the reduced General and Administrative expenses, specifically regarding the one-time nature of the severance reversals and the absence of IPO-related costs.